Just got this email from Roche announcing a grant program to pay registration and travel fees for the AGBT meeting if you are using Roche-454 sequencing or Roche-Nimblegen arrays as part of your work (see below). Seems like this would have some of the same conflict of interest issues as a pharma company paying someone to give a talk. I note - I participated in a session supported by 454 at a meeting but paid my own way to avoid this type of conflict of interest issue. Anyone have opinions on this? Is this a common pharma method creeping its way more and more into genomics?
Subscribe to:
Post Comments (Atom)
Most recent post
My Ode to Yolo Bypass
Gave my 1st ever talk about Yolo Bypass and my 1st ever talk about Nature Photography. Here it is ...
-
I have a new friend in Google Scholar Updates I have written about the Updates system before and if you want more information please see...
-
See Isolation and sequence-based characterization of a koala symbiont: Lonepinella koalarum Paper based on PhD thesis work of Katie Dahlha...
-
Just got this press release by email. I am sick of receiving dozens of unsolicited press releases, especially those in topics not related ...
Interesting post - I hadn't considered being sponsored by the makers of a piece of equipment you use to be much of a conflict of interest (although admittedly I am newish to the world of scientific conferences). I can see it being a problem if your abstract is basically "Roche equipment is amazing" but do you think it is also a problem if the abstract is "using roche equipment we found..." ?
ReplyDeleteIf you did receive the grant isn't it normal practice to write this on your poster/say it in your presentation? That would point out any possible conflict of interest to your audience. Or do you think that is not enough?